Gefapixant: Merck's Laboratory

gefapixant: 

The Merck's Gefapixant has reported significantly lowering cough frequency as compared to placebo at week 12 and 24 in patient with Refractory and Unexplained Chronic Cough.

Introduction: 

Gefapixant is the drug under clinical trial used for treating refractory and unexplained chronic cough. These molecule drug directly act on the P2X3 receptor. 

P2X3 are the receptor found on the sensory nerve fiber, predominantly c fiber and in the airway linning.